Physician profile
Douglas Eric Faig
NPI 1053340521
$17,950.52
in general payments reported to CMS, 2019-2025
27 companies · $3,562 in 2025
The $3,562 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,944 · 2020: $2,150 · 2021: $536 · 2022: $3,956 · 2023: $1,477 · 2024: $326 · 2025: $3,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Consulting Fee: $1,250 · Food and Beverage: $1,180 · Travel and Lodging: $875 · Education: $59.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Consulting Fee | $1,250.00 |
| Food and Beverage | $1,179.56 |
| Travel and Lodging | $875.14 |
| Education | $59.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $8,125.45 | 2019-2024 | Tagrisso |
| Avyxa Pharma, LLC | $3,063.25 | 2025 | |
| Pfizer INC. | $1,862.88 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,412.17 | 2021-2022 | |
| Seagen INC. | $1,250.00 | 2023 | |
| Genzyme Corporation | $468.14 | 2021-2025 | |
| Janssen Biotech, INC. | $450.63 | 2019-2025 | Carvykti, Darzalex, Erleada |
| Sanofi-Aventis U.S. LLC | $300.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $217.09 | 2019-2025 | |
| Athenex Pharmaceutical Division, LLC | $150.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.88 | 2019-2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $111.18 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Eisai INC. | $47.90 | 2019 | |
| Incyte Corporation | $44.88 | 2025 | Jakafi, Niktimvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $43.80 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.06 | 2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $21.30 | 2025 | Lynozyfic |
| Alexion Pharmaceuticals, INC. | $20.09 | 2025 | Ultomiris |
| Lilly USA, LLC | $19.93 | 2023 | Retevmo, Jaypirca |
| Coherus Oncology, INC. | $18.85 | 2024 | |
| Sobi, INC | $18.26 | 2022 | |
| Astellas Pharma US INC | $17.08 | 2023 | Padcev |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Pharmaand Gmbh | $15.79 | 2025 | Rubraca |
| Tolmar, INC. | $14.92 | 2025 | Rubraca, Eligard |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Faig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.